ScinoPharm Taiwan (台灣神隆), which makes active pharmaceutical ingredients, yesterday reported a 36.95 percent decline in net profit for last quarter because of slow orders and mounting price pressure.
Net profit fell to NT$121.4 million (US$3.97 million), or NT$0.17 per share, last quarter, from NT$192.56 million, or NT$0.28 per share, a quarter ago, according to the company’s filing to the Taiwan Stock Exchange. The figure was 51.92 percent lower than NT$252.5 million, or NT$0.36 per share, a year earlier, filing said.
“Sales of weight-loss drug Qsymia were lower than expected, resulting in high inventory level for the drug’s developer, US-based Vivus Inc. Therfore, the company reduced its purchase of ingredients for the drug this year,” company chief financial officer Patricia Chou (周珮芬) said in an investors’ conference yesterday.
Lower sales not only affected ScinoPharm’s top line but also reduced its utilization rate, Chou said.
The company also faced pressure from its clients that make generic drugs to cut prices, Chou added.
ScinoPharm Taiwan also had difficulty acquiring paclitaxel, which is used to make “10 dab” for manufacturing ingredients for cancer drugs, because of unstable weather in Europe, Chou said, adding that higher prices for paclitaxel is expected to reduce the firm’s gross margin by 5 percent this year.
The company’s gross margin dropped to 37.23 percent last quarter, from 43.56 percent the previous quarter and 42.75 percent a year ago, according to filing.
Revenue for ScinoPharm Taiwan also declined to NT$1 billion, down 13.04 percent from NT$1.15 billion the previous quarter and 19.35 percent from NT$1.24 billion a year ago, the filing said.
Chou said prices for paclitaxel would return to normal next year, but the company’s utilization rate would still remain low over the next year.
Chou said ScinoPharm Taiwan’s sales and profit would rise significantly after next year, when the US Food and Drug Administration completes its inspection of the company’s factory in Changshu, China to make active pharmaceutical ingredients.
Meanwhile, the company said it inked a deal with Nanjing King-friend Biochemical Pharmaceutical Co (南京健友生化) to make ingredients for Regadenson, which is used to facilitate the examination of human hearts.
The drug is expected to receive approval to enter the Chinese market in 2020, with expected sales of 200 million to 300 million Chinese yuan (US$32.68 million to US$49.02 million) per year, ScinoPharm Taiwan said, citing Nanjing King-friend.
Softbank Group Corp plans to keep a stake in the chip designer Arm Ltd, even if it sells a partial interest to Nvidia Corp, the Nikkei reported. The companies are negotiating terms, the newspaper reported, citing sources. Softbank might take a stake in Nvidia after it buys Arm, the report said. Nvidia and Arm might also merge through a share swap, and Softbank would become a major shareholder in the combined company, it said. The two parties aim to reach a deal in the next few weeks, the sources said, asking not to be identified because the information is private. Nvidia is the
END TO SPECULATION: The hotel’s management contract has been extended, despite reports that it wanted to end its alliance with Hyatt Hotels over a deal with Riant Capital Singapore-based Hong Leong Hotel Development Ltd (豐隆大飯店股份) yesterday said it has extended a management contract to ensure the continued presence of the Grand Hyatt brand in Taipei, ending rumors that the two sides were parting ways. “We are pleased Hyatt is able to come to terms on the extension of the management contract of Grand Hyatt Taipei,” said Kwek Leng Beng (郭令明), executive chairman of City Developments Ltd (城市發展) and Millennium & Copthorne Hotels Ltd (千禧國敦酒店). Hong Leong Hotel Development is a subsidiary of Millennium, and both fall under the Hong Leong Group (豐隆集團). The Grand Hyatt Taipei (台北君悅大飯店), owned and built by
Gold surged to a fresh record on Friday, fueled by US dollar weakness and low interest rates, while silver headed for its best month since 1979. Spot bullion is up more than 10 percent this month, as US real yields lingered near record lows. While the ferocity of rallies in gold and silver cooled in the middle of the week, most market watchers predict there might be more gains ahead. Both metals have added about 30 percent this year, with gold and silver exchange-traded funds boosting holdings to a record, as concern about the fallout from the COVID-19 pandemic fuels demand for
MOVING FROM CHINA? The article did not name the company, but Foxconn, Wistron and Pegatron were among firms chosen for a production-linked incentive plan in India An Apple Inc vendor is looking at shifting six production lines to India from China, which could result in US$5 billion of iPhone exports from the South Asian nation, the Times of India reported, citing people familiar with the matter who it did not identify. The establishment of the facility would create about 55,000 jobs over about a year, the newspaper reported, not naming the Apple vendor. It would also cater to the domestic market and expand operations to include tablets and laptops, the newspaper reported. Samsung Electronics Co and Apple’s assembly partners are among 22 companies that have pledged 110 billion
RSS